SCA
TARO

Snowden Capital Advisors’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Snowden Capital Advisors’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,732
Closed -$980K – 304
2016
Q2 		$980K Buy
6,732
+322
+5% +$45.7K 0.3% 127
2016
Q1 		$918K Buy
+6,410
New +$910K 0.31% 126

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Snowden Capital Advisors's TARO Position: Q3 2016 in Review

Snowden Capital Advisors sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2016, closing a stake of 6,732 shares — an estimated $980K sold.

Snowden Capital Advisors first reported a position in TARO in Q1 2016 and held it in 2 quarters. The position peaked at $980K in Q2 2016. 162 funds tracked by Wall St. Rank hold TARO as of Q3 2016.

  • Snowden Capital Advisors reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2016 after selling out during the quarter.
  • Snowden Capital Advisors sold 6,732 Taro Pharmaceutical Industries Ltd. shares in Q3 2016, an estimated $980K.
  • Snowden Capital Advisors first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2016 and held it in 2 quarters.
  • Snowden Capital Advisors's Taro Pharmaceutical Industries Ltd. position peaked at $980K in Q2 2016.
  • 162 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2016.

Based on Snowden Capital Advisors's 13F filing for Q3 2016, filed 8 Jan 2024.